Four years of open-label extension follow-up on zorevunersen showed durable seizure reductions and sustained cognition and behavior gains in Dravet syndrome, evidence Stoke Therapeutics and Biogen say supports the drug's disease-modifying potential ahead of a pivotal Phase 3 readout in the third quarter of 2027.
Stoke Therapeutics and Biogen took the stage at the European Epilepsy Congress in Athens this week armed with four years of open-label extension results for zorevunersen, reporting that the antisense drug cut seizures durably and lifted cognition and behavior in Dravet syndrome patients — evidence the partners say points to disease modification rather than symptom control.
"Seizures are the most acute symptom of Dravet syndrome but the disease affects nearly every aspect of a child's development, from their ability to communicate with loved ones to skills like dressing and feeding themselves," Helen Cross, professor at University College London Great Ormond Street Institute of Child Health, said in a statement tied to the Sept. 5-9 meeting. "The continuing improvements in cognition and behavior shown in these studies suggest zorevunersen has the potential to narrow the developmental gap between these children and their neurotypical peers."
The data cover more than five years of clinical experience across two Phase 1/2a studies and ongoing open-label extensions. Four-year results showed statistically significant improvements in cognition and behavior at years one through four versus open-label baseline, measured on the Vineland-3 adaptive behavior scale, alongside substantial reductions in the most severe seizure types through three years — the leading risk factor for sudden unexpected death in epilepsy, or SUDEP, which is the primary cause of premature death in the disease. Quality-of-life gains were documented through 28 months. Zorevunersen was generally well tolerated across more than 930 administered doses, with elevated cerebrospinal fluid protein common but no serious clinical manifestations or hydrocephalus reported.
The mechanism sets the drug apart from standard care. Zorevunersen is an antisense oligonucleotide built on Stoke's TANGO platform that boosts production of functional NaV1.1 protein from the unaffected copy of the SCN1A gene, targeting the root cause of a disorder where up to 57 percent of patients fail to reach a 50 percent seizure reduction on the best available anti-seizure medicines. That genetic approach, rather than symptom suppression, is what underpins the disease-modifying claim — and the commercial case for a therapy aimed at a severe developmental and epileptic encephalopathy affecting an estimated 38,000 people across the U.S., U.K., EU-4 and Japan, with roughly 16,000 in the U.S. alone.
The pivotal global Phase 3 EMPEROR study has completed enrollment in its primary analysis population of 162 patients in the U.S., U.K. and Japan, with a further 34 enrolled in Europe. China enrollment is still underway and expected to finish in the second half of 2026. The trial randomizes patients two to 18 years old 1:1 to zorevunersen via intrathecal injection or a sham comparator over a 52-week treatment period, with the primary endpoint measuring change in major motor seizure frequency at week 28.
A data readout is anticipated in the third quarter of 2027 to complete a planned rolling U.S. New Drug Application submission to the FDA in the second half of that year. Zorevunersen already holds orphan drug designation from the FDA and European Medicines Agency, plus FDA rare pediatric disease and Breakthrough Therapy designations and a similar breakthrough tag from China's Center for Drug Evaluation. The Phase 1/2a and OLE results were published in the New England Journal of Medicine in March 2026.
Biogen co-develops zorevunersen under a collaboration in which Stoke keeps exclusive rights in the U.S., Canada and Mexico while Biogen holds rest-of-world commercialization. The larger partner brings commercial infrastructure to a rare-disease launch, though the near-term catalyst risk sits squarely with the EMPEROR readout. Across five tag-specific clinical-trial events, the average one-day share move was negative 1.67 percent, a reminder that positive early data have not consistently translated into sustained gains.
Biogen shares, up 23.1 percent year to date, closed at $216.65 on Aug. 31, with RBC Capital Markets raising its price target to $260 from $240 on an outperform rating. Stoke, the higher-beta pure play on the program, carries the bulk of the binary risk into 2027. The four-year durability data narrow the developmental gap argument that will anchor the launch narrative, but the market's verdict on whether zorevunersen becomes the first approved disease-modifying therapy for Dravet syndrome will not come until the Phase 3 numbers land next year.
This article is for informational purposes only and does not constitute investment advice.
